Q4 Earnings Forecast for Insulet Issued By Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs dropped their Q4 2024 EPS estimates for shares of Insulet in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will post earnings of $0.99 per share for the quarter, down from their previous forecast of $1.00. The consensus estimate for Insulet’s current full-year earnings is $3.10 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.22 EPS, FY2027 earnings at $6.46 EPS and FY2028 earnings at $7.75 EPS.

PODD has been the subject of several other research reports. Citigroup boosted their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler boosted their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James boosted their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Insulet stock opened at $275.10 on Monday. The firm’s fifty day moving average price is $234.83 and its 200 day moving average price is $206.03. The company has a market capitalization of $19.29 billion, a price-to-earnings ratio of 47.11, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. Insulet has a 12-month low of $156.00 and a 12-month high of $279.40. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet in the second quarter valued at approximately $32,000. Venturi Wealth Management LLC boosted its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC boosted its holdings in shares of Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.